Respiratory - September 2020

Respiratory - September 2020

Propeller health enters Japan via collaboration with Novartis to connect the Propeller digital health platform to Enerzair and Atectura Breezhaler

26 Aug 2020

  • Patients in Japan using Enerzair and Atectura Breezhaler to manage uncontrolled Asthma will have the option to enroll in Propeller’s digital health platform to help manage their condition
  • Propeller’s platform works by attaching a sensor to the inhaler which then delivers objective data on medication use to the Propeller app on the patient’s smartphone
  • The app will send patient reminders and keep a record of adherence data over time
  • Enerzair Breezhaler was approved in Japan on June 29, 2020 for the treatment of bronchial Asthma; Atectura Breezhaler was also approved as a LABA/ICS combination Asthma treatment
  • This is the second collaboration between Propeller health and Novartis ex-US where both companies first collaborated in Europe in July 2020

Propeller health enters Japan with digital health sensor for Enerzair and Atectura Breezhaler

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Remarks: 

  • About Propeller’s digital  –
    • Propeller’s digital health platform includes a sensor and app. A transparent capsule lets users see the medication; the inhaler also includes an attached CE marked sensor that connects with Propeller’s smartphone app
    • Propeller’s app also delivers medication reminders to the user and tracks adherence data, which can then be shared with clinicians

– Dr. Kowndinya, CI Scientists

For full story click here

Home